IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial February 23, 2026 Read More »
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026 September 28, 2026 Read More »
Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst August 28, 2026 Read More »
